Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VAREX IMAGING CORPORATION

(VREX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Varex Imaging : Announces Partial Redemption of Senior Secured Notes

07/01/2021 | 09:06am EDT

Varex Imaging Corporation (Nasdaq: VREX) today announced the partial redemption in the amount of $30 million of its $300 million 7.875% senior secured notes due 2027, in accordance with the terms and conditions of the governing indenture. The redemption price of the redeemed notes will be 103.0% of the principal amount thereof, plus accrued and unpaid interest from and including April 15, 2021 to but excluding the redemption date of July 15, 2021.

“Our improving financial performance and cash generation in recent quarters is enabling us to pay down some of our outstanding debt and reduce our interest expense,” said Sam Maheshwari, Chief Financial Officer of Varex Imaging Corporation.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate Varex’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,000 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements concerning the announced partial note redemption; and any statements using the terms “believe,” “expect,” “intend,” “outlook,” “future,” “anticipate,” “will,” “could,” “estimate,” “guidance,” or similar statements are forward-looking statements that involve risks and uncertainties that could cause Varex’s actual results to differ materially from those anticipated. While forward-looking statements are based on assumptions and analyses made by us that we believe to be reasonable under the circumstances, whether actual results and developments will meet our expectations and predictions depend on a number of risks and uncertainties which could cause our actual results, performance, and financial condition to differ materially from our expectations. Such risks and uncertainties include the severity and duration of the COVID-19 pandemic and its impact on both the global economy and the Varex’s business; our ability to maintain compliance with our financial covenants; shifts in product mix; not receiving the intended benefit of current or future restructurings or cost reduction actions; the continued impact of tariffs or a global trade war on Varex’s products and customer purchasing patterns; global economic conditions; demand for and delays in delivery of products of Varex or its customers; litigation costs; Varex’s ability to develop, commercialize and deploy new products; the impact of reduced or limited demand by purchasers of certain X-ray products; the impact of competitive products and pricing; the ability to remediate material weaknesses in internal control; and the other risks listed from time to time in our filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. Any forward-looking statements made by us in this news release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Varex assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.


ę Business Wire 2021
All news about VAREX IMAGING CORPORATION
08/04VAREX IMAGING : Management's Discussion and Analysis of Financial Condition and Results of..
AQ
08/04VAREX IMAGING : Swings to Fiscal Q3 Non-GAAP Gain, Revenue Rises; Sets Fiscal Q4 Targets
MT
08/03VAREX IMAGING : ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER FISCAL YEAR 2021 (Form 8-K)
PU
08/03Varex Imaging Corporation Provides Revenue Guidance for the Fourth Quarter of 2021
CI
08/03VAREX IMAGING CORP : Results of Operations and Financial Condition, Financial Statements a..
AQ
08/03VAREX IMAGING : Earnings Flash (VREX) VAREX IMAGING CORPORATION Reports Q3 Revenue $211.2M..
MT
08/03VAREX IMAGING : Earnings Flash (VREX) VAREX IMAGING CORPORATION Posts Q3 EPS $0.40, vs. St..
MT
08/03VAREX IMAGING : Announces Financial Results for Third Quarter Fiscal Year 2021
BU
08/03Varex Imaging Corporation Reports Earnings Results for the Third Quarter Ended July 2, ..
CI
07/20VAREX IMAGING : Schedules Third Quarter Fiscal Year 2021 Earnings Release and Conference C..
BU
More news
Analyst Recommendations on VAREX IMAGING CORPORATION
More recommendations
Financials (USD)
Sales 2021 807 M - -
Net income 2021 33,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 32,5x
Yield 2021 -
Capitalization 1 049 M 1 049 M -
Capi. / Sales 2021 1,30x
Capi. / Sales 2022 1,24x
Nbr of Employees 2 000
Free-Float 99,3%
Chart VAREX IMAGING CORPORATION
Duration : Period :
Varex Imaging Corporation Technical Analysis Chart | VREX | US92214X1063 | MarketScreener
Technical analysis trends VAREX IMAGING CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 26,61 $
Average target price 37,25 $
Spread / Average Target 40,0%
EPS Revisions
Managers and Directors
Sunny S. Sanyal President, Chief Executive Officer & Director
Shubham Maheshwari Chief Financial & Accounting Officer
RuŰdiger Naumann-Etienne Chairman
David Frick Vice President-Operations
Victor Garcia Vice President-Regulatory & Quality Compliance
Sector and Competitors
1st jan.Capi. (M$)
VAREX IMAGING CORPORATION59.53%1 049
SARTORIUS AG68.12%43 908
BIOTAGE AB (PUBL)72.81%1 819
REVENIO GROUP OYJ13.32%1 757
CELLAVISION AB (PUBL)31.73%1 120
908 DEVICES INC.-43.74%886